Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available
Adequate bone marrow, kidney, and liver function
Measurable disease using RECIST v1.1
ECOG 0 or 1
Life expectancy ≥ 3 months
You may not be if
Prior treatment with any ADC with a topoisomerase 1 inhibitor payload
Prior treatment with any CEACAM5 targeted therapy
Uncontrolled cardiovascular disease
Uncontrolled active Hepatitis B, Hepatitis C, or HIV infection
History of interstitial lung disease
Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start
Clareo Health | A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors
